Takeda-Midosuji-Bldg

Filed under: |
Takeda's NINLARO fails to meet PFS primary endpoint in TOURMALINE-MM2 trial in newly diagnosed multiple myeloma patients.

Leave a Reply

Your email address will not be published. Required fields are marked *